Fulcrum Therapeutics

Graphic of a fork in the road with arrows pointing in either direction
Biotech

BMS' MyoKardia scraps heart muscle pact with Fulcrum

MyoKardia, a biotech BMS bought in 2020, was working with Fulcrum to find cardiomyopathy targets but recently decided to end the alliance.
Nick Paul Taylor Mar 5, 2025 5:30am
failure crash no fail rocket cancelled end

Sanofi's $80M bet on Fulcrum dystrophy drug ends in phase 3 fail

Sep 12, 2024 9:30am
pay deal hand over cash licensing transaction money

Sanofi pays Fulcrum $80M for rights to phase 3 rare disease drug

May 13, 2024 7:09am
parachute chutes

Bayer undergoes leadership shake-up—Chutes & Ladders

Mar 22, 2024 9:30am
Go sign green light

Fulcrum's SCD program is back in business after FDA lifts hold

Aug 22, 2023 8:33am
FDA

Cancer concerns behind FDA hold on Fulcrum's sickle cell med

Mar 9, 2023 10:59am